Skip to main content



) --




) hit a new 52-week high Friday as it is currently trading at $82.26, above its previous 52-week high of $82.22 with 37,961 shares traded as of 9:35 a.m. ET. Average volume has been 1.3 million shares over the past 30 days.

Gen-Probe has a market cap of $3.74 billion and is part of the


sector and

diversified services

industry. Shares are up 38.8% year to date as of the close of trading on Thursday.

TheStreet Recommends

Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. The company has a P/E ratio of 78.2, below the average diversified services industry P/E ratio of 79.7 and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Gen-Probe as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full

Gen-Probe Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center